Article(id=1325225456592618255, tenantId=1146029695717560320, journalId=1319690259887390882, issueId=1325225034792444105, articleNumber=null, orderNo=null, doi=10.16522/j.cnki.cjph.2026.05.001, pmid=null, cstr=null, oa=null, hot=null, price=null, onlineType=0, articleFormat=0, articleType=null, articleTypeStr=null, receivedDate=1751990400000, receivedDateStr=2025-07-09, revisedDate=null, revisedDateStr=null, acceptedDate=null, acceptedDateStr=null, onlineDate=1793887970350, onlineDateStr=2026-11-05, pubDate=1778342400000, pubDateStr=2026-05-10, doiRegisterDate=null, doiRegisterDateStr=null, onlineIssueDate=1793887970350, onlineIssueDateStr=2026-11-05, onlineJustAcceptDate=null, onlineJustAcceptDateStr=null, onlineFirstDate=null, onlineFirstDateStr=null, sourceXml=null, magXml=null, createTime=1793887970350, creator=13701087609, updateTime=1793887970350, updator=13701087609, issue=Issue{id=1325225034792444105, tenantId=1146029695717560320, journalId=1319690259887390882, year='2026', volume='57', issue='5', pageStart='499', pageEnd='624', issueExtLink='null', onlineDate='null', pubDate='1778342400000', pubDateStr='2026-05-10', beforeIssueId=null, nextIssueId=null, price=null, status=1, issueComplete=1, articleOrder=1, issueType=-1, specialIssue=null, createTime=1793887869784, creator='13701087609', updateTime=1793935334440, updator='13701087609', preIssue=null, nextIssue=null, articleTotal=null, ext={EN=IssueExt(id=1325424116299342176, tenantId=1146029695717560320, journalId=1319690259887390882, issueId=1325225034792444105, language=EN, specialIssueTitle=, coverIllustrator=null, specialIssueEditor=, specialIssueAbout=), CN=IssueExt(id=1325424116299342177, tenantId=1146029695717560320, journalId=1319690259887390882, issueId=1325225034792444105, language=CN, specialIssueTitle=, coverIllustrator=null, specialIssueEditor=, specialIssueAbout=)}, issueFiles=null, downloadFileDto=null}, startPage=499, endPage=507, ext={EN=ArticleExt(id=1325225456798139152, articleId=1325225456592618255, tenantId=1146029695717560320, journalId=1319690259887390882, language=EN, title=Research Progress of Nanodelivery Systems for siRNA Drugs in Lung-targeted Therapy of Respiratory Diseases, columnId=1322624444355432649, journalTitle=Chinese Journal of Pharmaceuticals, columnName=Perspective & Review, runingTitle=null, highlight=null, articleAbstract=

Small interfering RNA(siRNA) is a programmable gene-silencing therapeutic agent that can specifically downregulate the expression of pathogenic genes through the RNA interference mechanism, thereby exhibiting significant potential in precision therapy for respiratory diseases. In recent years, siRNA agents targeting key pathogenic genes in respiratory diseases have shown promising therapeutic efficacy in disease models such as lung cancer, asthma,COPD, and idiopathic pulmonary fibrosis. However, naked siRNA suffers from several limitations, including poor in vivo stability, high susceptibility to nuclease degradation, low transmembrane delivery efficiency, difficulty in penetrating the pulmonary mucus barrier, and inadequate endosomal escape capability, which severely hinder its clinical translation. To address these challenges, various nanoscale delivery systems, including lipid nanoparticles, polymeric nanoparticles, viral vectors, inorganic nanomaterials, and exosomes, have been developed for the efficient delivery of siRNA to pulmonary lesions. Centered on the “disease - siRNA target - delivery system” framework, this review systematically summarizes the research progress of representative siRNA-based nanoscale delivery systems for respiratory diseases. It critically examines how different nanocarriers influence siRNA delivery efficiency with respect to systemic circulation stability, pulmonary targeting, mucus penetration, cellular uptake, and endosomal escape. Furthermore, it outlines optimization strategies such as passive targeting, ligand modification, stimuli-responsiveness, and biomimetic modification, aiming to provide a reference for further research and clinical translation of siRNA therapeutics for lung-targeted treatment of respiratory diseases.

, authors=Jiahui WANG, Fenghua GU*, authorsList=Jiahui WANG, Fenghua GU, authorCompany=null, correspAuthors=Fenghua GU, authorNote=null, correspAuthorsNote=null, copyrightStatement=null, copyrightOwner=null, extLink=null, articleAbsUrl=null, sourceXml=null, magXml=null, pdfUrl=null, pdf=null, pdfFileSize=null, pdfExtLink=null, richHtmlUrl=null, mobilePdfUrl=null, reviewReport=null, pdfFirstPage=null, abstractGraph=null, abstractGraphContent=null, abstractVideo=null, citation=null, cebUrl=null, magXmlContent=null, mapNumber=null, fund=null), CN=ArticleExt(id=1325225457167237905, articleId=1325225456592618255, tenantId=1146029695717560320, journalId=1319690259887390882, language=CN, title=siRNA药物纳米递送系统在呼吸系统疾病肺靶向治疗中的研究进展, columnId=1322624444544176331, journalTitle=中国医药工业杂志, columnName=专论与综述, runingTitle=null, highlight=null, articleAbstract=

小干扰RNA(siRNA)作为一种可编程的基因沉默药物,能通过RNA干扰机制特异性下调致病基因表达,在呼吸系统疾病精准治疗中展现出巨大潜力。近年来,针对呼吸系统疾病关键靶点的siRNA已在肺癌、哮喘、COPD及特发性肺纤维化等疾病模型中显示出良好的治疗前景。然而,裸siRNA存在体内稳定性差、易被核酸酶降解、跨膜转运效率低、难以穿透肺部黏液屏障、内体逃逸不足等问题,严重限制了临床转化。因此,脂质纳米颗粒、聚合物纳米粒、病毒载体、无机纳米材料及外泌体等多种纳米递送系统被用于siRNA在肺部病灶的高效递送。该文围绕“疾病—siRNA靶点—递送系统”这一主线,系统综述了呼吸系统疾病中代表性siRNA药物纳米递送系统的研究进展,重点分析了不同纳米载体在循环稳定性、肺部靶向性、黏液穿透、细胞摄取和内体逃逸等方面对siRNA递送效率的影响,并总结了被动靶向、配体修饰、环境响应及仿生修饰等优化策略,为siRNA药物在呼吸系统疾病肺靶向治疗中的进一步研究与临床转化提供参考。

, authors=王佳慧, 顾丰华*, authorsList=王佳慧, 顾丰华, authorCompany=null, correspAuthors=顾丰华, authorNote=

王佳慧,硕士研究生,专业方向:呼吸系统疾病药物评价。

, correspAuthorsNote=
顾丰华,硕士生导师,副教授,从事呼吸系统疾病药物的评价和研究。
, copyrightStatement=null, copyrightOwner=null, extLink=null, articleAbsUrl=null, sourceXml=25MTDRZXZ4ZQfNmHhUpdtw==, magXml=r27AwJ6jI6hVTCQUV0rqeQ==, pdfUrl=null, pdf=Dap+AMH7b1GIM7GYPXkLcw==, pdfFileSize=1468004, pdfExtLink=null, richHtmlUrl=null, mobilePdfUrl=null, reviewReport=null, pdfFirstPage=null, abstractGraph=null, abstractGraphContent=null, abstractVideo=null, citation=null, cebUrl=null, magXmlContent=PZBNPL0Mi9mgrEJzvU6g6g==, mapNumber=null, fund=null)}, authors=[Author(id=1325226078100390014, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1325225456592618255, orderNo=0, firstName=null, middleName=null, lastName=null, nameCn=null, orcid=null, stid=null, country=null, authorPic=null, dead=0, email=null, emailSecond=null, emailThird=null, correspondingAuthor=0, authorType=1, ext={EN=AuthorExt(id=1325226078175887488, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1325225456592618255, authorId=1325226078100390014, language=EN, stringName=Jiahui WANG, firstName=Jiahui, middleName=null, lastName=WANG, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=null, address=China State Institute of Pharmaceutical Industry, Shanghai 201203, bio=null, bioImg=null, bioContent=null, aboutCorrespAuthor=null), CN=AuthorExt(id=1325226078247190657, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1325225456592618255, authorId=1325226078100390014, language=CN, stringName=王佳慧, firstName=null, middleName=null, lastName=null, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=null, address=中国医药工业研究总院,上海 201203, bio={"content":"

王佳慧,硕士研究生,专业方向:呼吸系统疾病药物评价。

"}, bioImg=null, bioContent=

王佳慧,硕士研究生,专业方向:呼吸系统疾病药物评价。

, aboutCorrespAuthor=null)}, companyList=[AuthorCompany(id=1325226078012309626, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1325225456592618255, xref=null, ext=[AuthorCompanyExt(id=1325226078020698235, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1325225456592618255, companyId=1325226078012309626, language=EN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=China State Institute of Pharmaceutical Industry, Shanghai 201203), AuthorCompanyExt(id=1325226078029086844, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1325225456592618255, companyId=1325226078012309626, language=CN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=中国医药工业研究总院,上海 201203)])]), Author(id=1325226078322688131, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1325225456592618255, orderNo=1, firstName=null, middleName=null, lastName=null, nameCn=null, orcid=null, stid=null, country=null, authorPic=null, dead=0, email=null, emailSecond=null, emailThird=null, correspondingAuthor=1, authorType=1, ext={EN=AuthorExt(id=1325226078377214085, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1325225456592618255, authorId=1325226078322688131, language=EN, stringName=Fenghua GU, firstName=Fenghua, middleName=null, lastName=GU, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=*, address=China State Institute of Pharmaceutical Industry, Shanghai 201203, bio=null, bioImg=null, bioContent=null, aboutCorrespAuthor=null), CN=AuthorExt(id=1325226078477877382, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1325225456592618255, authorId=1325226078322688131, language=CN, stringName=顾丰华, firstName=null, middleName=null, lastName=null, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=*, address=中国医药工业研究总院,上海 201203, bio=null, bioImg=null, bioContent=null, aboutCorrespAuthor=null)}, companyList=[AuthorCompany(id=1325226078012309626, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1325225456592618255, xref=null, ext=[AuthorCompanyExt(id=1325226078020698235, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1325225456592618255, companyId=1325226078012309626, language=EN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=China State Institute of Pharmaceutical Industry, Shanghai 201203), AuthorCompanyExt(id=1325226078029086844, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1325225456592618255, companyId=1325226078012309626, language=CN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=中国医药工业研究总院,上海 201203)])])], keywords=[Keyword(id=1325226078620483719, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1325225456592618255, language=EN, orderNo=1, keyword=small interfering RNA), Keyword(id=1325226078687592584, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1325225456592618255, language=EN, orderNo=2, keyword=nanodelivery system), Keyword(id=1325226078758895753, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1325225456592618255, language=EN, orderNo=3, keyword=lung targeting), Keyword(id=1325226078838587530, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1325225456592618255, language=EN, orderNo=4, keyword=respiratory disease), Keyword(id=1325226078935056523, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1325225456592618255, language=EN, orderNo=5, keyword=gene silencing), Keyword(id=1325226079052497036, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1325225456592618255, language=EN, orderNo=6, keyword=research progress), Keyword(id=1325226079216074893, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1325225456592618255, language=CN, orderNo=1, keyword=小干扰RNA), Keyword(id=1325226079291572366, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1325225456592618255, language=CN, orderNo=2, keyword=纳米递送系统), Keyword(id=1325226079383847055, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1325225456592618255, language=CN, orderNo=3, keyword=肺部靶向), Keyword(id=1325226079471927440, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1325225456592618255, language=CN, orderNo=4, keyword=呼吸系统疾病), Keyword(id=1325226079543230609, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1325225456592618255, language=CN, orderNo=5, keyword=基因沉默), Keyword(id=1325226079635505298, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1325225456592618255, language=CN, orderNo=6, keyword=研究进展)], refs=[Reference(id=1325226079811666067, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1325225456592618255, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[1], rfOrder=0, authorNames=null, journalName=null, refType=null, unstructuredReference=GBD Chronic Respiratory Disease Collaborators.Prevalence and attributable health burden of chronic respiratory diseases,1990—2017: a systematic analysis for the Global Burden of Disease Study 2017 [J].Lancet Respir Med, 2020, 8(6):585-596., articleTitle=null, refAbstract=null), Reference(id=1325226079895552148, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1325225456592618255, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[2], rfOrder=1, authorNames=null, journalName=null, refType=null, unstructuredReference=张宏道, 高世琦, 吴立刚.小RNA药物研究进展与展望[J].生命的化学, 2024, 44(9): 1714-1727., articleTitle=null, refAbstract=null), Reference(id=1325226079962661013, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1325225456592618255, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[3], rfOrder=2, authorNames=null, journalName=null, refType=null, unstructuredReference=WANG J M, WANG P F, SHAO Y R, et al.Advancing treatment strategies: a comprehensive review of drug delivery innovations for chronic inflammatory respiratory diseases [J].Pharmaceutics, 2023, 15(8): 2151., articleTitle=null, refAbstract=null), Reference(id=1325226080038158486, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1325225456592618255, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[4], rfOrder=3, authorNames=null, journalName=null, refType=null, unstructuredReference=FAN Y L, YANG Z J.Inhaled siRNA formulations for respiratory diseases: from basic research to clinical application[J].Pharmaceutics, 2022, 14(6): 1193., articleTitle=null, refAbstract=null), Reference(id=1325226080109461655, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1325225456592618255, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[5], rfOrder=4, authorNames=null, journalName=null, refType=null, unstructuredReference=GUO S, ZHANG M J, HUANG Y Y.Three “E” challenges for siRNA drug development [J].Trends Mol Med, 2024,30(1): 13-24., articleTitle=null, refAbstract=null), Reference(id=1325226080172376216, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1325225456592618255, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[6], rfOrder=5, authorNames=null, journalName=null, refType=null, unstructuredReference=张琼丹, 陈朝霞, 李带瑶, 等.siRNA纳米递送系统研究进展[J].生物化学与生物物理进展, 2022, 49(6): 1018-1035., articleTitle=null, refAbstract=null), Reference(id=1325226080260456601, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1325225456592618255, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[7], rfOrder=6, authorNames=null, journalName=null, refType=null, unstructuredReference=KHAN S, REHMAN U, PARVEEN N, et al.siRNA therapeutics: insights, challenges, remedies and future prospects [J].Expert Opin Drug Deliv, 2023, 20(9): 1167-1187., articleTitle=null, refAbstract=null), Reference(id=1325226081959149722, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1325225456592618255, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[8], rfOrder=7, authorNames=null, journalName=null, refType=null, unstructuredReference=CHARBE N B, AMNERKAR N D, RAMESH B, et al.Small interfering RNA for cancer treatment: overcoming hurdles in delivery [J].Acta Pharm Sin B, 2020, 10(11): 2075-2109., articleTitle=null, refAbstract=null), Reference(id=1325226082043035803, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1325225456592618255, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[9], rfOrder=8, authorNames=null, journalName=null, refType=null, unstructuredReference=ZHANG J Y, CHEN B, GAN C Y, et al.A comprehensive review of small interfering RNAs(siRNAs): mechanism,therapeutic targets, and delivery strategies for cancer therapy[J].Int J Nanomedicine, 2023, 18: 7605-7635., articleTitle=null, refAbstract=null), Reference(id=1325226082370191516, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1325225456592618255, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[10], rfOrder=9, authorNames=null, journalName=null, refType=null, unstructuredReference=YANG G X, ZHOU D, DAI Y, et al.Construction of PEI-EGFR-PD-L1-siRNA dual functional nano-vaccine and therapeutic efficacy evaluation for lung cancer [J].Thorac Cancer, 2022, 13(21): 2941-2950., articleTitle=null, refAbstract=null), Reference(id=1325226082483437725, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1325225456592618255, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[11], rfOrder=10, authorNames=null, journalName=null, refType=null, unstructuredReference=IP S, MS S, AV K, et al.The mixture of siRNAs targeted to IL-4 and IL-13 genes effectively reduces the airway hyperreactivity and allergic inflammation in a mouse model of asthma [J].Int Immunopharmacol, 2022, 103: 108432., articleTitle=null, refAbstract=null), Reference(id=1325226082563129502, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1325225456592618255, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[12], rfOrder=11, authorNames=null, journalName=null, refType=null, unstructuredReference=EBENEZER O, OYEBAMIJI A K, OLANLOKUN J O,et al.Recent update on siRNA therapeutics [J].Int J Mol Sci, 2025, 26(8): 3456., articleTitle=null, refAbstract=null), Reference(id=1325226082647015583, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1325225456592618255, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[13], rfOrder=12, authorNames=null, journalName=null, refType=null, unstructuredReference=BISSERIER M, SUN X Q, FAZAL S, et al.Novel insights into the therapeutic potential of lung-targeted gene transfer in the most common respiratory diseases [J].Cells, 2022,11(6): 984., articleTitle=null, refAbstract=null), Reference(id=1325226082730901664, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1325225456592618255, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[14], rfOrder=13, authorNames=null, journalName=null, refType=null, unstructuredReference=VU THI H, TRAN L T, NGUYEN H Q, et al.RNA therapeutics for respiratory diseases [J].Prog Mol Biol Transl Sci, 2024, 203: 257-271., articleTitle=null, refAbstract=null), Reference(id=1325226082818982049, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1325225456592618255, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[15], rfOrder=14, authorNames=null, journalName=null, refType=null, unstructuredReference=DING L, TANG S Y, WYATT T A, et al.Pulmonary siRNA delivery for lung disease: review of recent progress and challenges [J].J Control Release, 2021, 330: 977-991., articleTitle=null, refAbstract=null), Reference(id=1325226082894479522, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1325225456592618255, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[16], rfOrder=15, authorNames=null, journalName=null, refType=null, unstructuredReference=KUZMOV A, MINKO T.Nanotechnology approaches for inhalation treatment of lung diseases [J].J Control Release,2015, 219: 500-518., articleTitle=null, refAbstract=null), Reference(id=1325226082978365603, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1325225456592618255, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[17], rfOrder=16, authorNames=null, journalName=null, refType=null, unstructuredReference=CHEN D Q, LIU J H, WU J, et al.Enhancing nanoparticle penetration through airway mucus to improve drug delivery efficacy in the lung [J].Expert Opin Drug Deliv, 2021,18(5): 595-606., articleTitle=null, refAbstract=null), Reference(id=1325226083049668772, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1325225456592618255, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[18], rfOrder=17, authorNames=null, journalName=null, refType=null, unstructuredReference=WILLIAMS T C, JACKSON D J, MALTBY S,et al.Rhinovirus-induced CCL17 and CCL22 in asthma exacerbations and differential regulation by STAT6 [J].Am J Respir Cell Mol Biol, 2021, 64(3): 344-356., articleTitle=null, refAbstract=null), Reference(id=1325226083116777637, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1325225456592618255, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[19], rfOrder=18, authorNames=null, journalName=null, refType=null, unstructuredReference=OCAMPO-ORTEGA S A, CABRERA-BECERRA S E,SIERRA-SANCHEZ V M, et al.Attenuation of pulmonary damage associated with COPD in a cadmium-exposed model due to the administration of a siRNA targeting PAD4 [J].Sci Pharm, 2024, 92(1): 12., articleTitle=null, refAbstract=null), Reference(id=1325226083192275110, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1325225456592618255, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[20], rfOrder=19, authorNames=null, journalName=null, refType=null, unstructuredReference=DENG X, YANG Y J, GAN L M, et al.Engineering lipid nanoparticles to enhance intracellular delivery of transforming growth factor-beta siRNA(siTGF-β1) via inhalation for improving pulmonary fibrosis post-bleomycin challenge [J].Pharmaceutics, 2025, 17(2): 157., articleTitle=null, refAbstract=null), Reference(id=1325226083280355495, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1325225456592618255, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[21], rfOrder=20, authorNames=null, journalName=null, refType=null, unstructuredReference=BAI X, ZHAO G L, CHEN Q J, et al.Inhaled siRNA nanoparticles targeting IL11 inhibit lung fibrosis and improve pulmonary function post-bleomycin challenge [J].Sci Adv,2022, 8(25): eabn7162., articleTitle=null, refAbstract=null), Reference(id=1325226083364241576, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1325225456592618255, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[22], rfOrder=21, authorNames=null, journalName=null, refType=null, unstructuredReference=WADHWA A, BOBAK T R, BOHRMANN L, et al.Pulmonary delivery of siRNA-loaded lipid-polymer hybrid nanoparticles: effect of nanoparticle size [J].OpenNano,2023, 13: 100180., articleTitle=null, refAbstract=null), Reference(id=1325226083473293481, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1325225456592618255, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[23], rfOrder=22, authorNames=null, journalName=null, refType=null, unstructuredReference=QIU C, XIA F, ZHANG J Z, et al.Advanced strategies for overcoming endosomal/lysosomal barrier in nanodrug delivery[J].Research(Wash D C), 2023, 6: 0148., articleTitle=null, refAbstract=null), Reference(id=1325226083582345386, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1325225456592618255, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[24], rfOrder=23, authorNames=null, journalName=null, refType=null, unstructuredReference=SHIRLEY J L, de JONG Y P, TERHORST C, et al.Immune responses to viral gene therapy vectors [J].Mol Ther, 2020,28(3): 709-722., articleTitle=null, refAbstract=null), Reference(id=1325226083653648555, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1325225456592618255, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[25], rfOrder=24, authorNames=null, journalName=null, refType=null, unstructuredReference=HASSETT K J, BENENATO K E, JACQUINET E,et al.Optimization of lipid nanoparticles for intramuscular administration of mRNA vaccines [J].Mol Ther Nucleic Acids, 2019, 15: 1-11., articleTitle=null, refAbstract=null), Reference(id=1325226083745923244, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1325225456592618255, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[26], rfOrder=25, authorNames=null, journalName=null, refType=null, unstructuredReference=DILLIARD S A, CHENG Q, SIEGWART D J.On the mechanism of tissue-specific mRNA delivery by selective organ targeting nanoparticles [J].Proc Natl Acad Sci U S A,2021, 118(52): e2109256118., articleTitle=null, refAbstract=null), Reference(id=1325226083817226413, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1325225456592618255, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[27], rfOrder=26, authorNames=null, journalName=null, refType=null, unstructuredReference=van ZYL D G, MENDES L P, SEMPER R P, et al.Poly(2-methyl-2-oxazoline) as a polyethylene glycol alternative for lipid nanoparticle formulation [J].Front Drug Deliv, 2024, 4:1383038., articleTitle=null, refAbstract=null), Reference(id=1325226083913695406, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1325225456592618255, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[28], rfOrder=27, authorNames=null, journalName=null, refType=null, unstructuredReference=PANOVICH P M, GANESAN A, ANGADI A R, et al.Recent advances in the application of polymeric nanoparticles to the pulmonary delivery of mRNA [J].Nanomedicine(Lond), 2025: 1-17., articleTitle=null, refAbstract=null), Reference(id=1325226084005970095, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1325225456592618255, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[29], rfOrder=28, authorNames=null, journalName=null, refType=null, unstructuredReference=ZHAO G L, HO W, CHU J X, et al.Inhalable siRNA nanoparticles for enhanced tumor-targeting treatment of KRAS-mutant non-small-cell lung cancer [J].ACS Appl Mater Interfaces, 2023, 15(26): 31273-31284., articleTitle=null, refAbstract=null), Reference(id=1325226084098244784, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1325225456592618255, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[30], rfOrder=29, authorNames=null, journalName=null, refType=null, unstructuredReference=WANG Y F, UKWATTAGE V, XIONG Y J, et al.Advancing endosomal escape of polymeric nanoparticles: towards improved intracellular delivery [J].Mater Horiz, 2025,12(11): 3622-3632., articleTitle=null, refAbstract=null), Reference(id=1325226084186325169, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1325225456592618255, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[31], rfOrder=30, authorNames=null, journalName=null, refType=null, unstructuredReference=TAGHDIRI M, MUSSOLINO C.Viral and non-viral systems to deliver gene therapeutics to clinical targets [J].Int J Mol Sci, 2024, 25(13): 7333., articleTitle=null, refAbstract=null), Reference(id=1325226084266016946, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1325225456592618255, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[32], rfOrder=31, authorNames=null, journalName=null, refType=null, unstructuredReference=YUDAEVA A, KOSTYUSHEVA A, KACHANOV A, et al.Clinical and translational landscape of viral gene therapies [J].Cells, 2024, 13(22): 1916., articleTitle=null, refAbstract=null), Reference(id=1325226084333125811, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1325225456592618255, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[33], rfOrder=32, authorNames=null, journalName=null, refType=null, unstructuredReference=CHAN Y K, WANG S K, CHU C J, et al.Engineering adeno-associated viral vectors to evade innate immune and inflammatory responses [J].Sci Transl Med, 2021, 13(580):eabd3438., articleTitle=null, refAbstract=null), Reference(id=1325226084404428980, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1325225456592618255, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[34], rfOrder=33, authorNames=null, journalName=null, refType=null, unstructuredReference=XU B L, LI S S, SHI R, et al.Multifunctional mesoporous silica nanoparticles for biomedical applications [J].Signal Transduct Target Ther, 2023, 8(1): 435., articleTitle=null, refAbstract=null), Reference(id=1325226084496703669, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1325225456592618255, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[35], rfOrder=34, authorNames=null, journalName=null, refType=null, unstructuredReference=WENG C M, LI G H, ZHANG D D, et al.Nanoscale porphyrin metal-organic frameworks deliver siRNA for alleviating early pulmonary fibrosis in acute lung injury [J].Front Bioeng Biotechnol, 2022, 10: 939312., articleTitle=null, refAbstract=null), Reference(id=1325226084576395446, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1325225456592618255, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[36], rfOrder=35, authorNames=null, journalName=null, refType=null, unstructuredReference=NHAVENE E P F, ANDRADE G F, FARIA J A Q A,et al.Biodegradable polymers grafted onto multifunctional mesoporous silica nanoparticles for gene delivery [J].ChemEngineering, 2018, 2(2): 24., articleTitle=null, refAbstract=null), Reference(id=1325226084651892919, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1325225456592618255, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[37], rfOrder=36, authorNames=null, journalName=null, refType=null, unstructuredReference=NAIR A, CHANDRASHEKHAR H R, DAY C M,et al.Polymeric functionalization of mesoporous silica nanoparticles: biomedical insights [J].Int J Pharm, 2024,660: 124314., articleTitle=null, refAbstract=null), Reference(id=1325226084739973304, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1325225456592618255, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[38], rfOrder=37, authorNames=null, journalName=null, refType=null, unstructuredReference=SHAO M M, LOPES D, LOPES J, et al.Exosome membrane-coated nanosystems: exploring biomedical applications in cancer diagnosis and therapy [J].Matter,2023, 6(3): 761-799., articleTitle=null, refAbstract=null), Reference(id=1325226086409306297, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1325225456592618255, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[39], rfOrder=38, authorNames=null, journalName=null, refType=null, unstructuredReference=LI Z F, YANG L L, WANG H Z, et al.Non-small-cell lung cancer regression by siRNA delivered through exosomes that display EGFR RNA aptamer [J].Nucleic Acid Ther, 2021,31(5): 364-374., articleTitle=null, refAbstract=null), Reference(id=1325226086484803770, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1325225456592618255, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[40], rfOrder=39, authorNames=null, journalName=null, refType=null, unstructuredReference=PRENCIPE G, TABAKMAN S M, WELSHER K, et al.PEG branched polymer for functionalization of nanomaterials with ultralong blood circulation [J].J Am Chem Soc, 2009,131(13): 4783-4787., articleTitle=null, refAbstract=null), Reference(id=1325226086577078459, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1325225456592618255, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[41], rfOrder=40, authorNames=null, journalName=null, refType=null, unstructuredReference=BOZZER S, GRIMALDI M C, De MASO L, et al.Stealth-engineered albumin-coated nanoparticles for targeted therapy:effective drug delivery and tumor suppression in xenograft-zebrafish model [J].Int J Nanomedicine, 2024, 19: 13267-13286., articleTitle=null, refAbstract=null), Reference(id=1325226086660964540, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1325225456592618255, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[42], rfOrder=41, authorNames=null, journalName=null, refType=null, unstructuredReference=NAKAMURA Y, MOCHIDA A, CHOYKE P L, et al.Nanodrug delivery: is the enhanced permeability and retention effect sufficient for curing cancer? [J].Bioconjug Chem,2016, 27(10): 2225-2238., articleTitle=null, refAbstract=null), Reference(id=1325226086753239229, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1325225456592618255, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[43], rfOrder=42, authorNames=null, journalName=null, refType=null, unstructuredReference=SHARIFI M, CHO W C, ANSARIESFAHANI A, et al.An updated review on EPR-based solid tumor targeting nanocarriers for cancer treatment [J].Cancers(Basel), 2022,14(12): 2868., articleTitle=null, refAbstract=null), Reference(id=1325226086832931006, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1325225456592618255, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[44], rfOrder=43, authorNames=null, journalName=null, refType=null, unstructuredReference=MURALIDHARAN R, BABU A, AMREDDY N, et al.Tumor-targeted nanoparticle delivery of HuR siRNA inhibits lung tumor growth in vitro and in vivo by disrupting the oncogenic activity of the RNA-binding protein HuR [J].Mol Cancer Ther, 2017, 16(8): 1470-1486., articleTitle=null, refAbstract=null), Reference(id=1325226086891651263, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1325225456592618255, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[45], rfOrder=44, authorNames=null, journalName=null, refType=null, unstructuredReference=STEFFENS R C, WAGNER E.Directing the way-receptor and chemical targeting strategies for nucleic acid delivery [J].Pharm Res, 2023, 40(1): 47-76., articleTitle=null, refAbstract=null), Reference(id=1325226087000703168, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1325225456592618255, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[46], rfOrder=45, authorNames=null, journalName=null, refType=null, unstructuredReference=PARHIZ H, SHUVAEV V V, PARDI N, et al.PECAM-1 directed re-targeting of exogenous mRNA providing two orders of magnitude enhancement of vascular delivery and expression in lungs independent of apolipoprotein E-mediated uptake [J].J Control Release, 2018, 291: 106-115., articleTitle=null, refAbstract=null), Reference(id=1325226087084589249, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1325225456592618255, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[47], rfOrder=46, authorNames=null, journalName=null, refType=null, unstructuredReference=FAN D H, CAO Y K, CAO M Q, et al.Nanomedicine in cancer therapy [J].Signal Transduct Target Ther, 2023,8(1): 293., articleTitle=null, refAbstract=null), Reference(id=1325226087176863938, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1325225456592618255, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[48], rfOrder=47, authorNames=null, journalName=null, refType=null, unstructuredReference=MAN R C H, QIU Y S, LEUNG S W S, et al.Co-delivery of PD-L1- and EGFR-targeting siRNAs by synthetic PEG12-KL4 peptide to the lungs as potential strategy against non-small cell lung cancer [J].Eur J Pharm Biopharm, 2024, 195: 114177., articleTitle=null, refAbstract=null), Reference(id=1325226087449493700, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1325225456592618255, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[49], rfOrder=48, authorNames=null, journalName=null, refType=null, unstructuredReference=虞矫娇, 蔡栅愉, 俞茂承, 等.小干扰RNA药物在慢性病领域的研究新进展:从临床前到临床[J].药学进展, 2024,48(8): 579-591., articleTitle=null, refAbstract=null)], funds=null, companyList=[AuthorCompany(id=1325226078012309626, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1325225456592618255, xref=null, ext=[AuthorCompanyExt(id=1325226078020698235, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1325225456592618255, companyId=1325226078012309626, language=EN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=China State Institute of Pharmaceutical Industry, Shanghai 201203), AuthorCompanyExt(id=1325226078029086844, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1325225456592618255, companyId=1325226078012309626, language=CN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=中国医药工业研究总院,上海 201203)])], figs=null, attaches=null, journal=Journal(id=1319689822849302687, delFlag=0, nameCn=中国医药工业杂志, nameEn=Chinese Journal of Pharmaceuticals, nameHistory1=null, nameHistory2=null, issn=1001-8255, eissn=null, cn=31-1243/R, coden=ZYGZEA, periodic=0, language=CN, oaType=null, ccby=null, superviseOffice=null, ownerOffice=null, pubOffice=null, editorOffice=null, officeType=null, aims=null, clcCode=null, officeProv=null, officeCity=null, officeAddr=null, officeZip=null, officeEmail=null, officePhone=null, editDirector=null, officeDirector=null, officeDirectorPhone=null, officeStaffNum=null, officeEmpNum=null, coverPicUrl=etiWDuwx2KO274LHw88KJA==, journalPrice=null, startedYear=null, abbrevIsoEn=Chinese Journal of Pharmaceuticals, journalRemark=null, publicationField=null, createdTime=1792568172420, updatedTime=1792747450744, createdBy=18614031015, updatedBy=13701087609, firstLetterCn=Z, firstLetterEn=Z, subjectCode=Medical and Pharmaceutical Sciences, subjectName=null, subjectCodeEn=Medical and Pharmaceutical Sciences, subjectNameEn=null, picCn=etiWDuwx2KO274LHw88KJA==, picEn=ip9NF4dK57AmNrCiZ6hmdw==, jcr=null, cjcr=null, exts=[JournalExt(id=1320441770761105589, language=CN, name=中国医药工业杂志, nameHistory1=null, nameHistory2=null, managedBy=, sponsoredBy=, publishedBy=, editorOffice=, officeProv=null, officeCity=null, officeAddr=, officeZip=, editDirector=, officeDirector=null, officePhone=null, coverPicUrl=null, journalRemark=, submitArticleUrl=null, websiteUrl=, createdTime=1792747450771, updatedTime=1792747450771, createdBy=13701087609, updatedBy=13701087609, submissionGuidelinesUrl=, submissionAuthorUrl=https://zgyygyauthor.cast.org.cn/webm, submissionEditorUrl=https://zgyygyeditor.cast.org.cn/webm, submissionReviewUrl=https://zgyygyauthor.cast.org.cn/webm, submissionCeEditorUrl=https://zgyygyeditor.cast.org.cn/webm, submissionAeEditorUrl=https://zgyygyeditor.cast.org.cn/webm, option={"copyright":""}), JournalExt(id=1320441770819825846, language=EN, name=Chinese Journal of Pharmaceuticals, nameHistory1=null, nameHistory2=null, managedBy=, sponsoredBy=, publishedBy=, editorOffice=, officeProv=null, officeCity=null, officeAddr=, officeZip=, editDirector=, officeDirector=null, officePhone=null, coverPicUrl=null, journalRemark=, submitArticleUrl=null, websiteUrl=, createdTime=1792747450785, updatedTime=1792747450785, createdBy=13701087609, updatedBy=13701087609, submissionGuidelinesUrl=, submissionAuthorUrl=https://zgyygyauthor.cast.org.cn/webm, submissionEditorUrl=https://zgyygyeditor.cast.org.cn/webm, submissionReviewUrl=https://zgyygyauthor.cast.org.cn/webm, submissionCeEditorUrl=https://zgyygyeditor.cast.org.cn/webm, submissionAeEditorUrl=https://zgyygyeditor.cast.org.cn/webm, option={"copyright":""})], databaseList=null, tenantJournalId=1319690259887390882, websiteList=[Website(id=1319720771623174732, webName=null, webTitle=null, webDomain=null, webCopyrigh=null, webIpcNo=null, seoTitle=null, seoKeywords=null, seoDescription=null, tenantJournalId=null, journalId=1319690259887390882, journalNameCn=null, journalNameEn=null, grayFlag=null, tenantId=1146029695717560320, platformId=null, journalGroupId=null, journalGroupNameCn=null, journalGroupNameEn=null, type=1, domain=https://castjournals.cast.org.cn/joweb/zgyygy/CN, language=CN, createTime=1792575551181, createBy=18614031015, updateTime=1792746040843, updateBy=18614031015, name=中国医药工业杂志-中文, tplId=1146099689490845704, title=中国医药工业杂志, delFlag=0, indexPage=/home, props=[WebsiteProps(id=1321428487504769041, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1319720771623174732, code=articleTextType, value=kx, createTime=1792982702375, updateTime=1792982702375, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428487475408910, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1319720771623174732, code=banner, value=https://castjournals.cast.org.cn/joweb/zgyygy/CN/file/pic?fileId=i/3+mr8MqWvs6ArWn9VK7w==, createTime=1792982702368, updateTime=1792982702368, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428487538323476, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1319720771623174732, code=grayFlag, value=0, createTime=1792982702383, updateTime=1792982702383, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428487462825997, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1319720771623174732, code=logo, value=https://castjournals.cast.org.cn/joweb/zgyygy/CN/file/pic?fileId=7mfvc3zMp/tsQUIOlJrNFQ==, createTime=1792982702365, updateTime=1792982702365, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428487571877910, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1319720771623174732, code=minRunFlag, value=0, createTime=1792982702391, updateTime=1792982702391, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428487496380432, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1319720771623174732, code=picServerUrl, value=https://castjournals.cast.org.cn/joweb/zgyygy/CN/file/pic, createTime=1792982702373, updateTime=1792982702373, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428487563489301, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1319720771623174732, code=silenceFlag, value=0, createTime=1792982702389, updateTime=1792982702389, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428487483797519, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1319720771623174732, code=staticResourcePath, value=https://castjournals.cast.org.cn/joweb/cast_kjdb_cn_619/, createTime=1792982702370, updateTime=1792982702370, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428487517351954, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1319720771623174732, code=themeColor, value=null, createTime=1792982702378, updateTime=1792982702378, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428487525740563, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1319720771623174732, code=themeStyle, value=.style-1 .main-menu ul>li { margin-right: 18px; } @media (max-width: 1442px) { .style-1 .main-menu ul>li a { font-size: 16px; padding: 10px 0; } }, createTime=1792982702380, updateTime=1792982702380, creator=18614031015, updator=18614031015)]), Website(id=1319720771702866512, webName=null, webTitle=null, webDomain=null, webCopyrigh=null, webIpcNo=null, seoTitle=null, seoKeywords=null, seoDescription=null, tenantJournalId=null, journalId=1319690259887390882, journalNameCn=null, journalNameEn=null, grayFlag=null, tenantId=1146029695717560320, platformId=null, journalGroupId=null, journalGroupNameCn=null, journalGroupNameEn=null, type=1, domain=https://castjournals.cast.org.cn/joweb/zgyygy/EN, language=EN, createTime=1792575551200, createBy=18614031015, updateTime=1792746037543, updateBy=18614031015, name=中国医药工业杂志-英文, tplId=1146101810881728533, title=Chinese Journal of Pharmaceuticals, delFlag=0, indexPage=/home, props=[WebsiteProps(id=1321428509638111261, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1319720771702866512, code=articleTextType, value=kx, createTime=1792982707652, updateTime=1792982707652, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428509579391002, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1319720771702866512, code=banner, value=https://castjournals.cast.org.cn/joweb/zgyygy/EN/file/pic?fileId=i/3+mr8MqWvs6ArWn9VK7w==, createTime=1792982707638, updateTime=1792982707638, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428509680054304, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1319720771702866512, code=grayFlag, value=0, createTime=1792982707662, updateTime=1792982707662, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428509566808089, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1319720771702866512, code=logo, value=https://castjournals.cast.org.cn/joweb/zgyygy/EN/file/pic?fileId=7mfvc3zMp/tsQUIOlJrNFQ==, createTime=1792982707635, updateTime=1792982707635, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428509701025826, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1319720771702866512, code=minRunFlag, value=0, createTime=1792982707667, updateTime=1792982707667, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428509629722652, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1319720771702866512, code=picServerUrl, value=https://castjournals.cast.org.cn/joweb/zgyygy/EN/file/pic, createTime=1792982707650, updateTime=1792982707650, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428509688442913, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1319720771702866512, code=silenceFlag, value=0, createTime=1792982707664, updateTime=1792982707664, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428509587779611, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1319720771702866512, code=staticResourcePath, value=https://castjournals.cast.org.cn/joweb/cast_kjdb_en_623/, createTime=1792982707640, updateTime=1792982707640, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428509663277086, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1319720771702866512, code=themeColor, value=null, createTime=1792982707658, updateTime=1792982707658, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428509671665695, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1319720771702866512, code=themeStyle, value=.style-1 .main-menu ul>li { margin-right: 18px; } @media (max-width: 1442px) { .style-1 .main-menu ul>li a { font-size: 16px; padding: 10px 0; } }, createTime=1792982707660, updateTime=1792982707660, creator=18614031015, updator=18614031015)])], journalTitle=中国医药工业杂志, weixinUrl=null, journalUrl=http://www.cjph.com.cn/, iacademicId=null, status=1, seqNo=null, journalTitleEn=Chinese Journal of Pharmaceuticals, journalPhotoCn=etiWDuwx2KO274LHw88KJA==, journalPhotoEn=ip9NF4dK57AmNrCiZ6hmdw==, journalFirstLetter=Z, journalRecommend=null, journalNew=null, journalCollection=null, jcrJf=null, cjcrJf=null, jcrJfStr=null, cjcrJfStr=null, submissionFirstDecision=null, sciSubjectClassification=null, casSubjectClassification=null, citeScore=null, totalCitationFrequency=null, icpCode=null, psCode=null, advertisingLicenseCode=null, copyrightInformation=null, country=null, option=, provinceCode=null, provinceName=null, collectFlag=false, interPubPlatform=, interPubPlatformUrl=null), detailUrlCn=https://castjournals.cast.org.cn/joweb/zgyygy/CN/10.16522/j.cnki.cjph.2026.05.001, detailUrlEn=https://castjournals.cast.org.cn/joweb/zgyygy/EN/10.16522/j.cnki.cjph.2026.05.001, pdfUrlCn=https://castjournals.cast.org.cn/joweb/zgyygy/CN/PDF/10.16522/j.cnki.cjph.2026.05.001, pdfUrlEn=https://castjournals.cast.org.cn/joweb/zgyygy/EN/PDF/10.16522/j.cnki.cjph.2026.05.001, aliStartDate=0, aliEndDate=0, collectionFlag=false, citedCount=null, citedUrl=null, previewStatus=0, delFlag=0, hasFullText=0, orderTime=1778342400000, fullTextJson=null, articleText=null, reference=null)
收藏切换
siRNA药物纳米递送系统在呼吸系统疾病肺靶向治疗中的研究进展
王佳慧 , 顾丰华 *
中国医药工业杂志 | 专论与综述 2026,57(5): 499-507
收起
收藏切换
中国医药工业杂志 |专论与综述 2026 , 57 (5) : 499 -507
siRNA药物纳米递送系统在呼吸系统疾病肺靶向治疗中的研究进展
全屏
[Author(id=1325226078100390014, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1325225456592618255, orderNo=0, firstName=null, middleName=null, lastName=null, nameCn=null, orcid=null, stid=null, country=null, authorPic=null, dead=0, email=null, emailSecond=null, emailThird=null, correspondingAuthor=0, authorType=1, ext={EN=AuthorExt(id=1325226078175887488, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1325225456592618255, authorId=1325226078100390014, language=EN, stringName=Jiahui WANG, firstName=Jiahui, middleName=null, lastName=WANG, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=null, address=China State Institute of Pharmaceutical Industry, Shanghai 201203, bio=null, bioImg=null, bioContent=null, aboutCorrespAuthor=null), CN=AuthorExt(id=1325226078247190657, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1325225456592618255, authorId=1325226078100390014, language=CN, stringName=王佳慧, firstName=null, middleName=null, lastName=null, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=null, address=中国医药工业研究总院,上海 201203, bio={"content":"

王佳慧,硕士研究生,专业方向:呼吸系统疾病药物评价。

"}, bioImg=null, bioContent=

王佳慧,硕士研究生,专业方向:呼吸系统疾病药物评价。

, aboutCorrespAuthor=null)}, companyList=[AuthorCompany(id=1325226078012309626, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1325225456592618255, xref=null, ext=[AuthorCompanyExt(id=1325226078020698235, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1325225456592618255, companyId=1325226078012309626, language=EN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=China State Institute of Pharmaceutical Industry, Shanghai 201203), AuthorCompanyExt(id=1325226078029086844, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1325225456592618255, companyId=1325226078012309626, language=CN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=中国医药工业研究总院,上海 201203)])]), Author(id=1325226078322688131, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1325225456592618255, orderNo=1, firstName=null, middleName=null, lastName=null, nameCn=null, orcid=null, stid=null, country=null, authorPic=null, dead=0, email=null, emailSecond=null, emailThird=null, correspondingAuthor=1, authorType=1, ext={EN=AuthorExt(id=1325226078377214085, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1325225456592618255, authorId=1325226078322688131, language=EN, stringName=Fenghua GU, firstName=Fenghua, middleName=null, lastName=GU, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=*, address=China State Institute of Pharmaceutical Industry, Shanghai 201203, bio=null, bioImg=null, bioContent=null, aboutCorrespAuthor=null), CN=AuthorExt(id=1325226078477877382, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1325225456592618255, authorId=1325226078322688131, language=CN, stringName=顾丰华, firstName=null, middleName=null, lastName=null, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=*, address=中国医药工业研究总院,上海 201203, bio=null, bioImg=null, bioContent=null, aboutCorrespAuthor=null)}, companyList=[AuthorCompany(id=1325226078012309626, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1325225456592618255, xref=null, ext=[AuthorCompanyExt(id=1325226078020698235, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1325225456592618255, companyId=1325226078012309626, language=EN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=China State Institute of Pharmaceutical Industry, Shanghai 201203), AuthorCompanyExt(id=1325226078029086844, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1325225456592618255, companyId=1325226078012309626, language=CN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=中国医药工业研究总院,上海 201203)])])]
王佳慧, 顾丰华*
作者信息
  • 中国医药工业研究总院,上海 201203
通讯作者:
顾丰华,硕士生导师,副教授,从事呼吸系统疾病药物的评价和研究。
作者简介:

王佳慧,硕士研究生,专业方向:呼吸系统疾病药物评价。

Research Progress of Nanodelivery Systems for siRNA Drugs in Lung-targeted Therapy of Respiratory Diseases
Jiahui WANG, Fenghua GU*
Affiliations
  • China State Institute of Pharmaceutical Industry, Shanghai 201203
出版时间: 2026-05-10 doi: 10.16522/j.cnki.cjph.2026.05.001
文章导航
收藏切换

小干扰RNA(siRNA)作为一种可编程的基因沉默药物,能通过RNA干扰机制特异性下调致病基因表达,在呼吸系统疾病精准治疗中展现出巨大潜力。近年来,针对呼吸系统疾病关键靶点的siRNA已在肺癌、哮喘、COPD及特发性肺纤维化等疾病模型中显示出良好的治疗前景。然而,裸siRNA存在体内稳定性差、易被核酸酶降解、跨膜转运效率低、难以穿透肺部黏液屏障、内体逃逸不足等问题,严重限制了临床转化。因此,脂质纳米颗粒、聚合物纳米粒、病毒载体、无机纳米材料及外泌体等多种纳米递送系统被用于siRNA在肺部病灶的高效递送。该文围绕“疾病—siRNA靶点—递送系统”这一主线,系统综述了呼吸系统疾病中代表性siRNA药物纳米递送系统的研究进展,重点分析了不同纳米载体在循环稳定性、肺部靶向性、黏液穿透、细胞摄取和内体逃逸等方面对siRNA递送效率的影响,并总结了被动靶向、配体修饰、环境响应及仿生修饰等优化策略,为siRNA药物在呼吸系统疾病肺靶向治疗中的进一步研究与临床转化提供参考。

小干扰RNA  /  纳米递送系统  /  肺部靶向  /  呼吸系统疾病  /  基因沉默  /  研究进展

Small interfering RNA(siRNA) is a programmable gene-silencing therapeutic agent that can specifically downregulate the expression of pathogenic genes through the RNA interference mechanism, thereby exhibiting significant potential in precision therapy for respiratory diseases. In recent years, siRNA agents targeting key pathogenic genes in respiratory diseases have shown promising therapeutic efficacy in disease models such as lung cancer, asthma,COPD, and idiopathic pulmonary fibrosis. However, naked siRNA suffers from several limitations, including poor in vivo stability, high susceptibility to nuclease degradation, low transmembrane delivery efficiency, difficulty in penetrating the pulmonary mucus barrier, and inadequate endosomal escape capability, which severely hinder its clinical translation. To address these challenges, various nanoscale delivery systems, including lipid nanoparticles, polymeric nanoparticles, viral vectors, inorganic nanomaterials, and exosomes, have been developed for the efficient delivery of siRNA to pulmonary lesions. Centered on the “disease - siRNA target - delivery system” framework, this review systematically summarizes the research progress of representative siRNA-based nanoscale delivery systems for respiratory diseases. It critically examines how different nanocarriers influence siRNA delivery efficiency with respect to systemic circulation stability, pulmonary targeting, mucus penetration, cellular uptake, and endosomal escape. Furthermore, it outlines optimization strategies such as passive targeting, ligand modification, stimuli-responsiveness, and biomimetic modification, aiming to provide a reference for further research and clinical translation of siRNA therapeutics for lung-targeted treatment of respiratory diseases.

small interfering RNA  /  nanodelivery system  /  lung targeting  /  respiratory disease  /  gene silencing  /  research progress
王佳慧, 顾丰华. siRNA药物纳米递送系统在呼吸系统疾病肺靶向治疗中的研究进展. 中国医药工业杂志, 2026 , 57 (5) : 499 -507 . DOI: 10.16522/j.cnki.cjph.2026.05.001
Jiahui WANG, Fenghua GU. Research Progress of Nanodelivery Systems for siRNA Drugs in Lung-targeted Therapy of Respiratory Diseases[J]. Chinese Journal of Pharmaceuticals, 2026 , 57 (5) : 499 -507 . DOI: 10.16522/j.cnki.cjph.2026.05.001

参考文献 引证文献
排序方式:
[1]
GBD Chronic Respiratory Disease Collaborators.Prevalence and attributable health burden of chronic respiratory diseases,1990—2017: a systematic analysis for the Global Burden of Disease Study 2017 [J].Lancet Respir Med, 2020, 8(6):585-596.
[2]
张宏道, 高世琦, 吴立刚.小RNA药物研究进展与展望[J].生命的化学, 2024, 44(9): 1714-1727.
[3]
WANG J M, WANG P F, SHAO Y R, et al.Advancing treatment strategies: a comprehensive review of drug delivery innovations for chronic inflammatory respiratory diseases [J].Pharmaceutics, 2023, 15(8): 2151.
[4]
FAN Y L, YANG Z J.Inhaled siRNA formulations for respiratory diseases: from basic research to clinical application[J].Pharmaceutics, 2022, 14(6): 1193.
[5]
GUO S, ZHANG M J, HUANG Y Y.Three “E” challenges for siRNA drug development [J].Trends Mol Med, 2024,30(1): 13-24.
[6]
张琼丹, 陈朝霞, 李带瑶, 等.siRNA纳米递送系统研究进展[J].生物化学与生物物理进展, 2022, 49(6): 1018-1035.
[7]
KHAN S, REHMAN U, PARVEEN N, et al.siRNA therapeutics: insights, challenges, remedies and future prospects [J].Expert Opin Drug Deliv, 2023, 20(9): 1167-1187.
[8]
CHARBE N B, AMNERKAR N D, RAMESH B, et al.Small interfering RNA for cancer treatment: overcoming hurdles in delivery [J].Acta Pharm Sin B, 2020, 10(11): 2075-2109.
[9]
ZHANG J Y, CHEN B, GAN C Y, et al.A comprehensive review of small interfering RNAs(siRNAs): mechanism,therapeutic targets, and delivery strategies for cancer therapy[J].Int J Nanomedicine, 2023, 18: 7605-7635.
[10]
YANG G X, ZHOU D, DAI Y, et al.Construction of PEI-EGFR-PD-L1-siRNA dual functional nano-vaccine and therapeutic efficacy evaluation for lung cancer [J].Thorac Cancer, 2022, 13(21): 2941-2950.
[11]
IP S, MS S, AV K, et al.The mixture of siRNAs targeted to IL-4 and IL-13 genes effectively reduces the airway hyperreactivity and allergic inflammation in a mouse model of asthma [J].Int Immunopharmacol, 2022, 103: 108432.
[12]
EBENEZER O, OYEBAMIJI A K, OLANLOKUN J O,et al.Recent update on siRNA therapeutics [J].Int J Mol Sci, 2025, 26(8): 3456.
[13]
BISSERIER M, SUN X Q, FAZAL S, et al.Novel insights into the therapeutic potential of lung-targeted gene transfer in the most common respiratory diseases [J].Cells, 2022,11(6): 984.
[14]
VU THI H, TRAN L T, NGUYEN H Q, et al.RNA therapeutics for respiratory diseases [J].Prog Mol Biol Transl Sci, 2024, 203: 257-271.
[15]
DING L, TANG S Y, WYATT T A, et al.Pulmonary siRNA delivery for lung disease: review of recent progress and challenges [J].J Control Release, 2021, 330: 977-991.
[16]
KUZMOV A, MINKO T.Nanotechnology approaches for inhalation treatment of lung diseases [J].J Control Release,2015, 219: 500-518.
[17]
CHEN D Q, LIU J H, WU J, et al.Enhancing nanoparticle penetration through airway mucus to improve drug delivery efficacy in the lung [J].Expert Opin Drug Deliv, 2021,18(5): 595-606.
[18]
WILLIAMS T C, JACKSON D J, MALTBY S,et al.Rhinovirus-induced CCL17 and CCL22 in asthma exacerbations and differential regulation by STAT6 [J].Am J Respir Cell Mol Biol, 2021, 64(3): 344-356.
[19]
OCAMPO-ORTEGA S A, CABRERA-BECERRA S E,SIERRA-SANCHEZ V M, et al.Attenuation of pulmonary damage associated with COPD in a cadmium-exposed model due to the administration of a siRNA targeting PAD4 [J].Sci Pharm, 2024, 92(1): 12.
[20]
DENG X, YANG Y J, GAN L M, et al.Engineering lipid nanoparticles to enhance intracellular delivery of transforming growth factor-beta siRNA(siTGF-β1) via inhalation for improving pulmonary fibrosis post-bleomycin challenge [J].Pharmaceutics, 2025, 17(2): 157.
[21]
BAI X, ZHAO G L, CHEN Q J, et al.Inhaled siRNA nanoparticles targeting IL11 inhibit lung fibrosis and improve pulmonary function post-bleomycin challenge [J].Sci Adv,2022, 8(25): eabn7162.
[22]
WADHWA A, BOBAK T R, BOHRMANN L, et al.Pulmonary delivery of siRNA-loaded lipid-polymer hybrid nanoparticles: effect of nanoparticle size [J].OpenNano,2023, 13: 100180.
[23]
QIU C, XIA F, ZHANG J Z, et al.Advanced strategies for overcoming endosomal/lysosomal barrier in nanodrug delivery[J].Research(Wash D C), 2023, 6: 0148.
[24]
SHIRLEY J L, de JONG Y P, TERHORST C, et al.Immune responses to viral gene therapy vectors [J].Mol Ther, 2020,28(3): 709-722.
[25]
HASSETT K J, BENENATO K E, JACQUINET E,et al.Optimization of lipid nanoparticles for intramuscular administration of mRNA vaccines [J].Mol Ther Nucleic Acids, 2019, 15: 1-11.
[26]
DILLIARD S A, CHENG Q, SIEGWART D J.On the mechanism of tissue-specific mRNA delivery by selective organ targeting nanoparticles [J].Proc Natl Acad Sci U S A,2021, 118(52): e2109256118.
[27]
van ZYL D G, MENDES L P, SEMPER R P, et al.Poly(2-methyl-2-oxazoline) as a polyethylene glycol alternative for lipid nanoparticle formulation [J].Front Drug Deliv, 2024, 4:1383038.
[28]
PANOVICH P M, GANESAN A, ANGADI A R, et al.Recent advances in the application of polymeric nanoparticles to the pulmonary delivery of mRNA [J].Nanomedicine(Lond), 2025: 1-17.
[29]
ZHAO G L, HO W, CHU J X, et al.Inhalable siRNA nanoparticles for enhanced tumor-targeting treatment of KRAS-mutant non-small-cell lung cancer [J].ACS Appl Mater Interfaces, 2023, 15(26): 31273-31284.
[30]
WANG Y F, UKWATTAGE V, XIONG Y J, et al.Advancing endosomal escape of polymeric nanoparticles: towards improved intracellular delivery [J].Mater Horiz, 2025,12(11): 3622-3632.
[31]
TAGHDIRI M, MUSSOLINO C.Viral and non-viral systems to deliver gene therapeutics to clinical targets [J].Int J Mol Sci, 2024, 25(13): 7333.
[32]
YUDAEVA A, KOSTYUSHEVA A, KACHANOV A, et al.Clinical and translational landscape of viral gene therapies [J].Cells, 2024, 13(22): 1916.
[33]
CHAN Y K, WANG S K, CHU C J, et al.Engineering adeno-associated viral vectors to evade innate immune and inflammatory responses [J].Sci Transl Med, 2021, 13(580):eabd3438.
[34]
XU B L, LI S S, SHI R, et al.Multifunctional mesoporous silica nanoparticles for biomedical applications [J].Signal Transduct Target Ther, 2023, 8(1): 435.
[35]
WENG C M, LI G H, ZHANG D D, et al.Nanoscale porphyrin metal-organic frameworks deliver siRNA for alleviating early pulmonary fibrosis in acute lung injury [J].Front Bioeng Biotechnol, 2022, 10: 939312.
[36]
NHAVENE E P F, ANDRADE G F, FARIA J A Q A,et al.Biodegradable polymers grafted onto multifunctional mesoporous silica nanoparticles for gene delivery [J].ChemEngineering, 2018, 2(2): 24.
[37]
NAIR A, CHANDRASHEKHAR H R, DAY C M,et al.Polymeric functionalization of mesoporous silica nanoparticles: biomedical insights [J].Int J Pharm, 2024,660: 124314.
[38]
SHAO M M, LOPES D, LOPES J, et al.Exosome membrane-coated nanosystems: exploring biomedical applications in cancer diagnosis and therapy [J].Matter,2023, 6(3): 761-799.
[39]
LI Z F, YANG L L, WANG H Z, et al.Non-small-cell lung cancer regression by siRNA delivered through exosomes that display EGFR RNA aptamer [J].Nucleic Acid Ther, 2021,31(5): 364-374.
[40]
PRENCIPE G, TABAKMAN S M, WELSHER K, et al.PEG branched polymer for functionalization of nanomaterials with ultralong blood circulation [J].J Am Chem Soc, 2009,131(13): 4783-4787.
[41]
BOZZER S, GRIMALDI M C, De MASO L, et al.Stealth-engineered albumin-coated nanoparticles for targeted therapy:effective drug delivery and tumor suppression in xenograft-zebrafish model [J].Int J Nanomedicine, 2024, 19: 13267-13286.
[42]
NAKAMURA Y, MOCHIDA A, CHOYKE P L, et al.Nanodrug delivery: is the enhanced permeability and retention effect sufficient for curing cancer? [J].Bioconjug Chem,2016, 27(10): 2225-2238.
[43]
SHARIFI M, CHO W C, ANSARIESFAHANI A, et al.An updated review on EPR-based solid tumor targeting nanocarriers for cancer treatment [J].Cancers(Basel), 2022,14(12): 2868.
[44]
MURALIDHARAN R, BABU A, AMREDDY N, et al.Tumor-targeted nanoparticle delivery of HuR siRNA inhibits lung tumor growth in vitro and in vivo by disrupting the oncogenic activity of the RNA-binding protein HuR [J].Mol Cancer Ther, 2017, 16(8): 1470-1486.
[45]
STEFFENS R C, WAGNER E.Directing the way-receptor and chemical targeting strategies for nucleic acid delivery [J].Pharm Res, 2023, 40(1): 47-76.
[46]
PARHIZ H, SHUVAEV V V, PARDI N, et al.PECAM-1 directed re-targeting of exogenous mRNA providing two orders of magnitude enhancement of vascular delivery and expression in lungs independent of apolipoprotein E-mediated uptake [J].J Control Release, 2018, 291: 106-115.
[47]
FAN D H, CAO Y K, CAO M Q, et al.Nanomedicine in cancer therapy [J].Signal Transduct Target Ther, 2023,8(1): 293.
[48]
MAN R C H, QIU Y S, LEUNG S W S, et al.Co-delivery of PD-L1- and EGFR-targeting siRNAs by synthetic PEG12-KL4 peptide to the lungs as potential strategy against non-small cell lung cancer [J].Eur J Pharm Biopharm, 2024, 195: 114177.
[49]
虞矫娇, 蔡栅愉, 俞茂承, 等.小干扰RNA药物在慢性病领域的研究新进展:从临床前到临床[J].药学进展, 2024,48(8): 579-591.
2026年第57卷第5期
159
48
0
引用本文
BibTeX
文章信息
doi: 10.16522/j.cnki.cjph.2026.05.001
  • 接收时间:2025-07-09
  • 首发时间:2026-11-05
  • 出版时间:2026-05-10
补充材料
相关文章
文章信息
作者
出版历史
  • 收稿日期:2025-07-09
基金
作者信息
    中国医药工业研究总院,上海 201203

通讯作者:

顾丰华,硕士生导师,副教授,从事呼吸系统疾病药物的评价和研究。
参考文献
分享链接
https://castjournals.cast.org.cn/joweb/zgyygy/CN/10.16522/j.cnki.cjph.2026.05.001
分享至
全文二维码

扫描看全文

引用本文
BibTeX
本文的引用情况
2种不同金属材料的力学参数
科
Family
属数
Number of
genus
种数
Number of
species
占总种数比例
Percentage of
total species (%)
属
Genus
种数
Number of
species
占总种数比例
Percentage of total
species (%)
鹅膏菌科Amanitaceae 2 11 5.26 鹅膏菌属 Amanita 10 4.78
小菇科 Mycenaceae 2 12 5.74 丝盖伞属 Inocybe 5 2.39
多孔菌科 Polyporaceae 8 14 6.70 蜡蘑属 Laccaria 5 2.39
红菇科 Russulaceae 3 23 11.00 小皮伞属 Marasmius 6 2.87
小菇属 Mycena 11 5.26
光柄菇属 Pluteus 5 2.39
红菇属 Russula 17 8.13
栓菌属 Trametes 5 2.39
关闭全屏